SecBot SecBot
8-K ·Filed Jul 22, 2026

PM

Philip Morris International Inc.
BULLISH
Impact 7/10
Horizonweeks Processed3mo ago SEC0001628280-26-049107
8-K Item 2.02: Earnings release
Actionable Insight ▲ Bullish

The strong Q2 beat and raised full-year guidance, combined with improving leverage metrics and a key FDA MRTP authorization for ZYN, reinforce the smoke-free transition thesis. Traders should watch for continued IQOS momentum outside Japan/Poland and the impact of accelerated U.S. investments in H2, which could pressure near-term margins but support long-term brand value. The Q3 guidance of $2.20-$2.25 provides a clear near-term catalyst.

DirectionBullish
Confidencehigh
Horizonweeks

How the stock moved after the report

BULLISH VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$194.30
T+0 close · Jul 22, 2026 · via day close
Latest settled
+2.88%
T+60 · $199.90
Vs SPY
−0.38%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Jul 22 $194.30entry
  2. T+1 · 4mo ago −1.64%α −0.40% · $191.12
  3. T+5 · 4mo ago +2.13%α +4.53% · $198.44
  4. T+20 · 3mo ago −2.25%α −5.15% · $189.93
  5. T+60 · 5w ago +2.88%α −0.38% · $199.90
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

PMI reported Q2 2026 adjusted diluted EPS of $2.20, a 15.2% increase YoY and well above the $2.04 consensus, driven by strong smoke-free revenue growth (up 11.7% reported, 9.7% organically) and robust pricing in combustibles. However, reported GAAP EPS fell 7.7% to $1.80 due to a $511M non-cash impairment of its RBH equity investment. The company updated its full-year adjusted EPS forecast to $8.26-$8.41, representing 9.5%-11.5% growth, and guided Q3 adjusted EPS of $2.20-$2.25, both above current Street expectations, reinforcing a positive operational trajectory despite currency headwinds.

Key Financial Metrics

EPS
$2.20
est $2.04 · +7.8%
Revenue
$11.2B
est $10.6B · +5.2% · +10.4% YoY
Rating
beat
Gross Margin
68.5%

Key Facts

  • Q2 2026 adjusted diluted EPS of $2.20 grew 15.2% YoY, beating the $2.04 consensus.
  • Total net revenues reached a record $11.2 billion, up 10.4% reported (7.6% organically), with smoke-free now ~42% of total.
  • Full-year 2026 adjusted diluted EPS forecast raised to $8.26-$8.41 (9.5%-11.5% growth), above the prior implied consensus.
  • Q3 2026 adjusted EPS guided to $2.20-$2.25, above the $2.04 consensus for the next quarter.
  • Reported GAAP EPS fell 7.7% to $1.80 due to a $511M non-cash impairment of the RBH (Canada) equity investment.
  • International Smoke-Free segment net revenues grew 14.2% (11.8% organically), driven by 8.0% volume growth and strong IQOS performance.
  • Net debt to adjusted EBITDA improved to 2.35x from 2.53x at year-end 2025, targeting ~2.0x by year-end.
  • FDA granted MRTP authorization to 20 ZYN variants on June 30, the first and only for a nicotine pouch product.

Financial Impact

Q2 adjusted EPS beat consensus by ~7.8% ($2.20 vs $2.04), with full-year guidance raised to $8.26-$8.41, implying ~$0.22 above the prior implied consensus at the midpoint.

revenueepsdebtdilution

Risk Factors

  • Currency headwinds: full-year currency impact revised to $0.15 favorable (down from $0.20), with Q3 expected to face an $0.08 unfavorable impact.
  • U.S. segment weakness: net revenues declined 0.7% in Q2 and 16.1% YTD, with adjusted OCI down 19.1% organically in Q2 due to investments and manufacturing costs.
  • Japan and Poland headwinds: excise-driven price increases in Japan and a flavor ban in Poland are creating transient volume pressure on IQOS HTU.

Market Snapshot

Price
$188.14
Volume
100
Exchange
NYSE
Sector
Cigarettes
Analyst Consensus
73% bullish (26 analysts)

Investment Themes

Consumer & Retail

Documents Analyzed

This report is based on 7 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001628280-26-049107
Document: earningsreleasepm-ex991xq2.htm0001628280-26-049107
Document: pm-20260722.htm0001628280-26-049107
Document: 0001628280-26-049107-index-headers.html0001628280-26-049107
Document: 0001628280-26-049107-index.html0001628280-26-049107
Document: 0001628280-26-049107.txt0001628280-26-049107
8-K Data (Synthetic)0001628280-26-049107

Track record

14 reports on PM

Performance horizon

3 of 3 bullish or bearish reports moved the stock their way by T+5. Best: +17.16% at T+20 after the Apr 22, 2026 report. 3 of 3 went positive at some point.

Filters
  1. Oct 29, 202619d ago Institutional Cluster Neutral 3/10 Entry $208.50 to $201.50 Now $194.38 −6.77% ▼ −3.36% +1.37% vs SPY
  2. Oct 21, 202627d ago 8-K Neutral 5/10 Entry $197.46 to $202.62 Now $194.38 −1.56% ▲ +2.61% +3.06% vs SPY
  3. Sep 18, 20268w ago 8-K Bullish 4/10 Entry $188.62 to $190.48 Now $194.38 +3.05% ▲ +0.99% −0.28% vs SPY
  4. Sep 8, 202610w ago 8-K Bullish 5/10 Entry $184.73 to $194.86 Now $194.38 +5.22% ▲ +5.48% +6.15% vs SPY
  5. Aug 24, 202612w ago 8-K Neutral 3/10 Entry $191.46 to $187.30 Now $194.38 +1.53% ▼ −2.17% −2.64% vs SPY
  6. Aug 3, 202615w ago 25-NSE Neutral 1/10 Entry $187.41 to $186.00 Now $194.38 +3.72% ▼ −0.75% −2.78% vs SPY
  7. Jul 22, 202616w ago 8-K Bullish 7/10 Viewing Entry $194.30 to $198.44 Now $194.38 +0.04% ▲ +2.13% +4.53% vs SPY
  8. Jun 29, 202620w ago 8-K Neutral 3/10 Entry $180.91 to $184.76 Now $194.38 +7.45% ▲ +2.13% +1.52% vs SPY
  9. Jun 11, 202622w ago 8-K Neutral 2/10 Entry $180.77 to $179.44 Now $194.38 +7.53% ▼ −0.74% −1.17% vs SPY
  10. May 20, 202625w ago 8-K Neutral 3/10 Entry $187.72 to $178.51 Now $194.38 +3.55% ▼ −4.91% −6.71% vs SPY
Showing 10 of 14

US Market Status

Market Closed · Opens Wed (< 1m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Jul 22, 2026